Treatment of Dermatitis (Atopic Dermatitis)
For adults with atopic dermatitis, begin with liberal moisturizers and topical corticosteroids as first-line therapy; for moderate-to-severe disease refractory to topicals, use dupilumab, tralokinumab, or JAK inhibitors (abrocitinib, baricitinib, upadacitinib) as these have the strongest evidence for efficacy and safety. 1, 2
Algorithmic Treatment Approach
Step 1: All Patients - Foundation Therapy
- Daily moisturizers (liberal application) - strong recommendation 3
- Daily bathing with soap-free cleansers 4
- These form the backbone of management regardless of severity
Step 2: Mild-to-Moderate Disease - Topical Therapy
First-line topical agents (strong recommendations):
- Topical corticosteroids - most established efficacy 3
- Topical calcineurin inhibitors (tacrolimus, pimecrolimus) - can be used with TCS 3, 4
Newer topical options (strong recommendations from 2025 update):
- Tapinarof cream - novel topical small molecule 1
- Roflumilast cream - PDE-4 inhibitor 1
- Topical JAK inhibitors (ruxolitinib) 3
Key caveat: Address steroid phobia directly with patients - side effects from appropriate TCS use are infrequent, but fear of steroids is a major barrier to adherence 5.
Step 3: Moderate-to-Severe Disease - Systemic Therapy
When topical therapy fails or disease substantially impairs quality of life, escalate to systemic agents.
Biologics (strong recommendations):
- Dupilumab - strongest evidence, no laboratory monitoring required 2
- Tralokinumab - strong recommendation 2
- Lebrikizumab with concomitant topical therapy - strong recommendation from 2025 update 1
- Nemolizumab with concomitant topical therapy - strong recommendation from 2025 update 1
Oral JAK Inhibitors (strong recommendations):
These newer agents (biologics and JAK inhibitors) have displaced older immunosuppressants as preferred options due to superior evidence quality.
Traditional Immunosuppressants (conditional recommendations):
- Cyclosporine - 3-5 mg/kg/day, limited to 1 year use 2
- Methotrexate - conditional recommendation 2
- Azathioprine - conditional recommendation 2
- Mycophenolate - conditional recommendation 2
These are reasonable alternatives but have weaker evidence and require more monitoring.
Phototherapy (conditional recommendation):
- Narrowband UVB is safe and effective for moderate-to-severe disease 2
Step 4: Adjunctive Therapies
Wet-wrap therapy:
- Reserved for moderate-to-severe flares or recalcitrant disease 3, 6
- Adds complexity but can be effective for acute control
What NOT to use:
- Systemic corticosteroids - conditional recommendation AGAINST due to rebound flares 2
- Oral antihistamines - not recommended, do not reduce pruritus 4, 5
- Topical antimicrobials/antiseptics - conditional recommendation against routine use 3
Critical Decision Points
When to escalate from topical to systemic therapy:
- Disease refractory to optimized topical therapy
- Widespread disease not manageable with topicals alone
- Substantial quality of life impairment
- Consider alternative diagnoses (allergic contact dermatitis, cutaneous lymphoma) if truly refractory 2
Choosing between systemic options: The 2024-2025 AAD guidelines give strong recommendations for dupilumab, tralokinumab, and all three JAK inhibitors, indicating these are preferred over traditional immunosuppressants which received only conditional recommendations 1, 2. The choice between biologics and JAK inhibitors depends on patient factors, but both classes have high-certainty evidence.
Important note on conjunctivitis: This is a common adverse effect with dupilumab, though no laboratory monitoring is required 2.
Practical Implementation
Most patients will use topical anti-inflammatory medications concomitantly with systemic therapies in real-world practice 2. The 2025 update specifically emphasizes using lebrikizumab and nemolizumab with concomitant topical therapy 1.
Therapeutic patient education improves outcomes and should include: disease recognition, trigger reduction, moisturization techniques, and proper medication use 5.